Marie Bosslett, Assistant Editor

Cold atmospheric plasma eases stubborn oral lichen planus in long follow-up study, with a new scoring system tracking pain, function, and healing.

A 24-week trial shows ruxolitinib cream sustains control and itch relief in moderate atopic dermatitis when steroids fail, with a positive safety profile.

Once-daily roflumilast cream brings fast itch relief, EASI-75 responses, and reassuring safety in 3–24 months, supporting a recent sNDA to the FDA.

Initial phase 2 data show abdakibart (AVTX-009) boosts HiSCR responses in moderate to severe HS, with favorable safety, paving way for phase 3.

This review of the latest dermatological studies includes insights on social media and DTC pediatric alopecia treatments, BTX-A and Profhilo combination therapy, diagnostic barriers in dermatomyositis, and more.

Daniel Condie, MD, shares kid-friendly sun safety tips, tanning bed warnings, and early skin cancer detection advice that clinicians can share with families and teens.

When combined with topicals, fire needle therapy boosted moderate acne clearance by week 8 and lowered IL-36/TSLP, with mostly mild adverse effects.

MRA commits a record $18.4M to global melanoma research, boosting rare-subtype collaboration, biorepositories, biomarkers, and next-gen therapies to combat rising cases.

Daniel Condie, MD, debunks common Gen Z tanning myths, warns base tans and sunscreen fears fuel early skin cancer, and explains Mohs care challenges.

As Melanoma Monday kicks off May's Skin Cancer Awareness Month, we're spotlighting the latest emerging data, evolving tools, and public health initiatives for clinicians.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Are at-home red light LED masks just a myth? Read more about the latest social media trend and discover how you should counsel your patients in the clinic.

Review the latest FDA pediatric dermatology updates, including dupilumab for childhood CSU, secukinumab for teen HS, and new CHE and infant eczema topical filings.

Explore top dermatology conferences and meetings in May 2026 and let us know which ones you'll be attending!

Dermatology Times is looking back on the top stories in dermatology from the month of April.

New sham-controlled trial finds niostem's at-home wearable using low-level electrical stimulation boosts hair density in men, with minimal adverse effects.

Learn more about the in-depth topics covered in the April 2026 print issue of Dermatology Times.

This review of the latest dermatological studies includes insights on Vitamin B12's connection to hyperpigmentation, treatment modalities for female pattern hair loss, 0.5% timolol maleate eye drops for rosacea, and more.

Maria Hordinsky, MD, breaks down phase 3 data that show topical clascoterone boosts male pattern hair growth for 12 months, targeting follicles without systemic hormonal adverse effects.

A new survey reveals the significant disconnect between dermocosmetic labeling and clinical reality. Explore more and vote in today's poll.

Aclaris Therapeutics shares promising Phase 1a data for ATI-052, showing long-acting dual Th2 blockade, and advances ATI-2138 toward Phase 2b lichen planus studies.

New research shows podiatry students struggle to spot psoriasis and eczema on darker skin, exposing dermatology training gaps and driving calls for inclusive teaching.

Learn how narcissistic traits and body dysmorphia could shape cosmetic dermatology visits, with red flags, screening tips, and safer patient care.

FDA will review a supplemental New Drug Application for topical roflumilast to treat infant AD with supporting trial data showing rapid itch relief and clear skin gains from week 1.

The FDA has accepted the resubmitted BLA for relabotulinumtoxinA, a next-generation neuromodulator for treating facial lines in adults.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

In case you missed it, this week we had news on the approval of dupilumab for pediatric CSU, phase 2b hair growth results with rezpegaldesleukin, multispecific biologics for AD, and more.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of April.

Potential FDA approval of TrenibotE was delayed due to manufacturing-related issues, with no concerns regarding safety, efficacy, or clinical trial data.

At the 2026 Winter Clinical Miami meeting, dermatology leaders emphasized that thriving careers require skills beyond clinical expertise.